Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C / 中华临床感染病杂志

ABSTRACT

China has largest number of chronic hepatitis C (CHC) patients, with complex distribution of genotypes, high proportion of refractory types and low diagnosis and treatment rate. It is necessary to explore accessible pan-genotype antiviral treatment protocols with high cure rate. Currently, the direct acting antiviral agents (DAAs) are recommended as the main treatment regimes by international guidelines for hepatitis C. Ravidasvir (RDV) is a new generation of NS5a inhibitor, which can be widely used in treatment of gene type 1, 2, 3, 4 and 6 CHC with strong antiviral activity and high resistance barrier. A number of clinical studies demonstrate that the combination of ravidavir with DAA S, such as second-generation protease inhibitor danoprevir (DNV) and nucleoside NS5b inhibitor sofosbuvir (SOF) have gained high cure rate and good safety for CHC patients. In this article, the results of related studies on ravidavir-based antiretroviral regimens in treatment of CHC are reviewed.